Therapeutic drug monitoring study on the switch from coformulated 600-mg efavirenz, tenofovir disoproxil fumarate, and emtricitabine to coformulated 400-mg efavirenz, tenofovir disoproxil fumarate, and lamivudine among HIV-positive patients with viral suppression
Journal
Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi
Journal Volume
54
Journal Issue
5
Date Issued
2021-10
Author(s)
Huang, Wei-Chieh
Huang, Chun-Kai
Huang, Sung-Hsi
Ou, Shyh-Tyan
Chen, Yi-Ting
Chen, Ya-Wen
Chang, Shu-Yuan
Liu, Wen-Chun
Abstract
This study evaluated the efavirenz (EFV) mid-dose plasma concentration (C12), clinical efficacy, and safety after the switch to a single-tablet regimen containing tenofovir disoproxil fumarate (TDF), lamivudine (3TC), and 400-mg EFV in virally suppressed HIV-positive Taiwanese who were receiving co-formulated TDF, emtricitabine (FTC), and 600-mg EFV.
Subjects
Antiretroviral therapy; Mid-dose plasma concentration; Neuropsychiatric adverse effects; Non-nucleoside reverse transcriptase inhibitor; Switch therapy
Type
journal article